CA3232809A1 - Engineered tgf-beta monomers and methods of use - Google Patents

Engineered tgf-beta monomers and methods of use Download PDF

Info

Publication number
CA3232809A1
CA3232809A1 CA3232809A CA3232809A CA3232809A1 CA 3232809 A1 CA3232809 A1 CA 3232809A1 CA 3232809 A CA3232809 A CA 3232809A CA 3232809 A CA3232809 A CA 3232809A CA 3232809 A1 CA3232809 A1 CA 3232809A1
Authority
CA
Canada
Prior art keywords
tgf
seq
amino acid
monomer
substitution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3232809A
Other languages
English (en)
French (fr)
Inventor
Andrew P. HINCK
Kristin DEPEAUX
Greg M. Delgoffe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of CA3232809A1 publication Critical patent/CA3232809A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA3232809A 2021-10-11 2022-10-11 Engineered tgf-beta monomers and methods of use Pending CA3232809A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163254249P 2021-10-11 2021-10-11
US63/254,249 2021-10-11
PCT/US2022/077879 WO2023064747A1 (en) 2021-10-11 2022-10-11 Engineered tgf-beta monomers and methods of use

Publications (1)

Publication Number Publication Date
CA3232809A1 true CA3232809A1 (en) 2023-04-20

Family

ID=85988028

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3232809A Pending CA3232809A1 (en) 2021-10-11 2022-10-11 Engineered tgf-beta monomers and methods of use

Country Status (9)

Country Link
US (1) US20240425559A1 (enExample)
EP (1) EP4416172A4 (enExample)
JP (1) JP2024537234A (enExample)
KR (1) KR20240082356A (enExample)
CN (1) CN118103390A (enExample)
AU (1) AU2022367394B2 (enExample)
CA (1) CA3232809A1 (enExample)
TW (1) TW202330579A (enExample)
WO (1) WO2023064747A1 (enExample)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW517059B (en) * 1994-07-25 2003-01-11 Ciba Geigy Ag New process for the production of biologically active protein
US11091523B2 (en) * 2016-11-18 2021-08-17 University of Pittsburgh—of the Commonwealth System of Higher Education Engineered TGF-β monomers and their use for inhibiting TGF-β signaling
JP2023539195A (ja) * 2020-08-27 2023-09-13 ユニバーシティ オブ ピッツバーグ － オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 組換えトランスフォーミング増殖因子（ｔｇｆ）－ベータ単量体をコードする腫瘍溶解性ウイルスおよびその使用

Also Published As

Publication number Publication date
AU2022367394B2 (en) 2026-03-19
KR20240082356A (ko) 2024-06-10
TW202330579A (zh) 2023-08-01
CN118103390A (zh) 2024-05-28
AU2022367394A1 (en) 2024-04-11
JP2024537234A (ja) 2024-10-10
WO2023064747A1 (en) 2023-04-20
EP4416172A4 (en) 2025-12-17
US20240425559A1 (en) 2024-12-26
EP4416172A1 (en) 2024-08-21

Similar Documents

Publication Publication Date Title
US9074009B2 (en) Stabilized MAML peptides and uses thereof
EP3027642A1 (en) Growth differentiation factor 15 (gdf-15) constructs
EP3341008A2 (en) Peptides binding to bfl-1
RU2685869C1 (ru) Варианты дизинтегрина и их фармацевтическое применение
US11033609B2 (en) Cyclic acetylcholinesterase C-terminal peptide in the treatment or prevention of cancer or metastasis
US12186376B2 (en) Methods of treating or preventing cancer with an agent that depletes tregs and a checkpoint inhibitor
AU2022367394B2 (en) Engineered tgf-beta monomers and methods of use
CN102993314A (zh) 一种抗肿瘤融合蛋白及其制备方法和用途
WO2008120263A2 (en) Prokineticins receptors antagonists, derivatives and uses thereof
HK40109585A (zh) 工程化TGF- β单体及其使用方法
WO2016097753A1 (en) Cyclic acetylcholinesterase c-terminal peptide in the treatment or prevention of cancer or metastasis
CN102470157A (zh) 广谱erbb配体结合分子及其制备和使用方法
JP7375163B2 (ja) Ｔｇｆ－ベータトラップ
KR20150010957A (ko) 넓은 스펙트럼 erbb 리간드 결합 분자 및 그의 사용 방법
CN110520144A (zh) 肽激酶抑制剂及其使用方法
WO2025217401A1 (en) A peptide inhibitor of the eya and pp2a-b55a interaction useful for myc-driven cancer therapy
CA3041727C (en) Engineered tgf-beta monomers and their use for inhibiting tgf-beta signaling

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240911

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240911

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240911

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250916

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250916